CY1108478T1 - Ιος της ομαδας pox με στοχοθετημενη ειδικοτητα μολυνσης - Google Patents
Ιος της ομαδας pox με στοχοθετημενη ειδικοτητα μολυνσηςInfo
- Publication number
- CY1108478T1 CY1108478T1 CY20081101247T CY081101247T CY1108478T1 CY 1108478 T1 CY1108478 T1 CY 1108478T1 CY 20081101247 T CY20081101247 T CY 20081101247T CY 081101247 T CY081101247 T CY 081101247T CY 1108478 T1 CY1108478 T1 CY 1108478T1
- Authority
- CY
- Cyprus
- Prior art keywords
- present
- poxviral
- vector
- targeted infection
- poxviral particle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε ένα σωματίδιο ιού της ομάδας pox που έχει μία ειδικότητα στοχοθετημένης μόλυνσης που παρέχεται από μία οντότητα ετερόλογου προσδέματος που είναι παρόν στην επιφάνεια του εν λόγω σωματιδίου ιού της ομάδας pox και που είναι ικανό να αναγνωρίζει ειδικά και να προσδένεται σε ένα μόριο αντι-πρόσδεμα που βρίσκεται στην επιφάνεια των κυττάρων στόχων. Η παρούσα εφεύρεση αφορά περαιτέρω σε ένα φορέα που περιέχει μία νουκλεοτιδική αλληλουχία που κωδικοποιεί για ένα χιμαιρικό πολυπεπτίδιο που περιλαμβάνει μία τέτοια οντότητα ετερόλογου προσδέματος και ολόκληρο ή μέρος του φυσικού πολυπεπτιδίου που βρίσκεται στην επιφάνεια του ιού της ομάδας pox. Η παρούσα εφεύρεση επιπλέον αφορά σε συνθέσεις που περιέχουν το σωματίδιο ιού της ομάδας pox ή των εν λόγω φορέα καθώς και στην χρήση τους για θεραπευτικούς και προφυλακτικούς λόγους. Η εφεύρεση έχει πολύ ειδικό ενδιαφέρον σε εφαρμογές γονιδιακής θεραπείας ειδικότερα στην πρόληψη και στην θεραπεία του καρκίνου στα θηλαστικά.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00440109 | 2000-04-14 | ||
US24608000P | 2000-11-07 | 2000-11-07 | |
EP01440009 | 2001-01-22 | ||
EP04077339A EP1516932B1 (en) | 2000-04-14 | 2001-04-12 | Poxvirus with targeted infection specificity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108478T1 true CY1108478T1 (el) | 2014-04-09 |
Family
ID=27223630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101247T CY1108478T1 (el) | 2000-04-14 | 2008-11-03 | Ιος της ομαδας pox με στοχοθετημενη ειδικοτητα μολυνσης |
Country Status (11)
Country | Link |
---|---|
US (1) | US7354591B2 (el) |
EP (2) | EP1146125B1 (el) |
JP (1) | JP2002320475A (el) |
AT (2) | ATE411392T1 (el) |
AU (1) | AU784776B2 (el) |
CA (1) | CA2341356C (el) |
CY (1) | CY1108478T1 (el) |
DE (2) | DE60107746T2 (el) |
DK (2) | DK1516932T3 (el) |
ES (2) | ES2312918T3 (el) |
PT (2) | PT1146125E (el) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
JP4802401B2 (ja) * | 2000-11-07 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | 標的化感染特異性を有するポックスウイルス |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
WO2003097846A1 (en) | 2002-05-16 | 2003-11-27 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
EP1369491A1 (en) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
AU2003251604A1 (en) * | 2002-06-26 | 2004-01-19 | F. C. Thomas Allnutt | Viruses and virus-like particles for multiple antigen and target display |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
US20050003024A1 (en) * | 2003-03-04 | 2005-01-06 | The Procter & Gamble Company | Regulation of mammalian hair growth |
JP3934673B1 (ja) * | 2003-06-18 | 2007-06-20 | ジェネラックス・コーポレイション | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
JP4842128B2 (ja) | 2003-07-21 | 2011-12-21 | トランジェーヌ、ソシエテ、アノニム | 新規多機能性サイトカイン |
WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
WO2007061141A1 (ja) | 2005-11-24 | 2007-05-31 | Genomidea, Inc. | 改変パラミクソウイルスおよびその作製方法 |
EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
MX2009008118A (es) | 2007-01-30 | 2009-10-13 | Transgene Sa | Polipeptido e2 del virus del papiloma usado para vacunacion. |
US8003363B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
WO2008138533A1 (en) * | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
FR2925067B1 (fr) * | 2007-12-18 | 2010-01-15 | Agronomique Inst Nat Rech | Vecteurs vaccinaux derives de leporipoxvirus |
KR20120052352A (ko) | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Hbv 감염을 치료하는 조성물 |
JP6415977B2 (ja) | 2011-04-15 | 2018-10-31 | ジェネラックス・コーポレイションGenelux Corporation | 弱毒化ワクシニアウイルスのクローン株およびその使用方法 |
US9708601B2 (en) * | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
EP3587455A1 (en) | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
JP7128177B2 (ja) | 2016-08-02 | 2022-08-30 | バクシネックス インコーポレーティッド | ワクシニアウイルス/真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法 |
KR20210108944A (ko) * | 2018-10-22 | 2021-09-03 | 아이셀킬렉스 테라퓨틱스 엘엘씨 | 돌연변이 백시니아 바이러스 및 이의 용도 |
GB2614309A (en) * | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
CN117625650A (zh) * | 2022-08-24 | 2024-03-01 | 康希诺(上海)生物研发有限公司 | 一种正痘病毒属mRNA疫苗及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2092323A1 (en) * | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
JPH08504098A (ja) * | 1992-11-20 | 1996-05-07 | ユニバーシティー オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 抗体−エンベロープ融合蛋白を含有するレトロウィルスベクターを用いた細胞種特異的な遺伝子転移 |
AU7097494A (en) * | 1993-06-01 | 1994-12-20 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
EP0786010A1 (en) * | 1994-03-04 | 1997-07-30 | University Of Medicine And Dentistry Of New Jersey | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope and wild-type envelope-fusion proteins |
-
2001
- 2001-04-10 CA CA2341356A patent/CA2341356C/en not_active Expired - Fee Related
- 2001-04-12 ES ES04077339T patent/ES2312918T3/es not_active Expired - Lifetime
- 2001-04-12 AU AU35190/01A patent/AU784776B2/en not_active Ceased
- 2001-04-12 DE DE60107746T patent/DE60107746T2/de not_active Expired - Lifetime
- 2001-04-12 ES ES01400942T patent/ES2232574T3/es not_active Expired - Lifetime
- 2001-04-12 AT AT04077339T patent/ATE411392T1/de active
- 2001-04-12 PT PT01400942T patent/PT1146125E/pt unknown
- 2001-04-12 PT PT04077339T patent/PT1516932E/pt unknown
- 2001-04-12 US US09/832,899 patent/US7354591B2/en not_active Expired - Fee Related
- 2001-04-12 DK DK04077339T patent/DK1516932T3/da active
- 2001-04-12 EP EP01400942A patent/EP1146125B1/en not_active Expired - Lifetime
- 2001-04-12 AT AT01400942T patent/ATE284970T1/de active
- 2001-04-12 EP EP04077339A patent/EP1516932B1/en not_active Expired - Lifetime
- 2001-04-12 DE DE60136232T patent/DE60136232D1/de not_active Expired - Lifetime
- 2001-04-12 DK DK01400942T patent/DK1146125T3/da active
- 2001-04-13 JP JP2001153216A patent/JP2002320475A/ja not_active Withdrawn
-
2008
- 2008-11-03 CY CY20081101247T patent/CY1108478T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE284970T1 (de) | 2005-01-15 |
DK1516932T3 (da) | 2008-12-01 |
CA2341356A1 (en) | 2001-10-14 |
ES2312918T3 (es) | 2009-03-01 |
EP1516932A1 (en) | 2005-03-23 |
PT1146125E (pt) | 2005-04-29 |
US20030165477A1 (en) | 2003-09-04 |
AU784776B2 (en) | 2006-06-15 |
EP1516932B1 (en) | 2008-10-15 |
ES2232574T3 (es) | 2005-06-01 |
US7354591B2 (en) | 2008-04-08 |
EP1146125B1 (en) | 2004-12-15 |
PT1516932E (pt) | 2009-01-23 |
JP2002320475A (ja) | 2002-11-05 |
DE60107746D1 (de) | 2005-01-20 |
DE60136232D1 (de) | 2008-11-27 |
DE60107746T2 (de) | 2005-12-01 |
EP1146125A1 (en) | 2001-10-17 |
AU3519001A (en) | 2001-10-18 |
DK1146125T3 (da) | 2005-04-25 |
CA2341356C (en) | 2011-10-11 |
ATE411392T1 (de) | 2008-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108478T1 (el) | Ιος της ομαδας pox με στοχοθετημενη ειδικοτητα μολυνσης | |
HRP20210766T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
PT1240325E (pt) | Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas | |
DE60042969D1 (de) | Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren | |
BR0007414A (pt) | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc | |
DK1623990T3 (da) | Sammensætninger og fremgangsmåder til tumorbehandling | |
DE69839571D1 (de) | Fibroblasten-wachstumsfaktor-19 | |
EP1385370A4 (en) | ANTIMICROBIAL POLYPEPTIDES AND USES THEREOF | |
NZ597998A (en) | Methods for treating cancer with mva | |
ES2332916T3 (es) | Composiciones y metodo para el tratamiento de tumores. | |
CA2461443A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
ES2324876T3 (es) | Composiciones y metodos para el diagnostico de tumores. | |
NO20032818D0 (no) | Polypeptider | |
DE60129069D1 (de) | Hepatitis B Virus Vektoren für Gentherapie | |
WO2003090778A3 (en) | Dna vaccine combined with an inducer of tumor cell apoptosis | |
DE602004032365D1 (de) | Modifizierter cea/b7-vektor | |
DE60140439D1 (de) | Hybridprotein und dafür kodierender vektor zur inhibition der angiogenese | |
WO2005068640A3 (en) | Modified ksa and uses thereof |